Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

CONCLUSIONS: Our results of the phase I/II trial demonstrated that the use of aaPRP in severe COVID-19 patients was safe and not associated with serious adverse events, which showed that aaPRP was a promising adjunctive therapy for severe COVID-19 patients.PMID:34306612 | PMC:PMC8285191 | DOI:10.1155/2021/5531873

Source: International Journal of Inflammation - July 26, 2021 Category: Allergy & Immunology Authors: Karina Karina Iis Rosliana Imam Rosadi Siti Sobariah Louis Martin Christoffel Rita Novariani Siti Rosidah Novy Fatkhurohman Yuli Hertati Nurlaela Puspitaningrum Wismo Reja Subroto Irsyah Afini Difky Ernanda Source Type: research